Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26620758 | 0.78 | CHRNB2 (0.40) | CHRNB2CHRNA4SIGMAR1 | |
| SCHEMBL2030277 | 0.75 | PLAU (0.45) | SIGMAR1 | |
| SCHEMBL3825586 | 0.75 | PLAU (0.45) | SIGMAR1 | |
| SCHEMBL8567210 | 0.75 | PLAU (0.45) | SIGMAR1 | |
| SCHEMBL30576492 | 0.75 | PLAU (0.45) | SIGMAR1 | |
| SCHEMBL24065105 | 0.74 | SIGMAR1 (0.46) | CHRNB2CHRNA4SIGMAR1CYP2A6 | |
| SCHEMBL29012624 | 0.74 | GABRP (0.38) | CHRNB2CHRNA4SIGMAR1 | |
| SCHEMBL30887799 | 0.74 | CYP1A2 (0.39) | CHRNB2CHRNA4SIGMAR1 | |
| SCHEMBL27010622 | 0.74 | ROCK2 (0.34) | CHRNB2CHRNA4SIGMAR1 | |
| SCHEMBL28308572 | 0.74 | CYP1A2 (0.39) | CHRNB2CHRNA4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230155-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY | 2025-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230155-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | CHRM5, CHRM4, CHRM1 | CHRNB2 17/4885CHRNA4 5/4885SIGMAR1 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.